T Ebert1,2, S Kralisch1,2, U Wurst1,2, M Scholz3,4, M Stumvoll1, P Kovacs2, M Fasshauer1,2, A Tönjes1,2. 1. Department of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany. 2. Leipzig University Medical Center, IFB AdiposityDiseases, Leipzig, Germany. 3. Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany. 4. LIFE Research Center, University of Leipzig, Leipzig, Germany.
Abstract
BACKGROUND/ OBJECTIVES: Irisin has been suggested as a novel myokine with beneficial effects in rodents. However, previous data in humans showed conflicting results regarding its association with metabolic phenotypes and regulation of secretion. Furthermore, although an association of rs726344 in FNDC5 (fibronectin type III domain containing 5) coding for irisin with insulin sensitivity was reported, the effects of genetic variation at this locus on irisin serum levels have not been investigated, so far. Therefore, we investigated circulating irisin and the associations with rs726344 in a cohort of >1000 subjects. SUBJECTS/ METHODS: Irisin serum concentrations were measured with enzyme-linked immunosorbent assay. Associations with metabolic parameters including renal function, glucose and lipid metabolism, inflammation, as well as adipokine profiles, were assessed in regression models. Dynamic changes of serum irisin were investigated during oral glucose tolerance test (OGTT) in a subset of the cohort (n=136). rs726344 was genotyped in all subjects and analyzed for associations with serum irisin and traits of the metabolic syndrome. RESULTS: Irisin was negatively associated with fat mass, fasting glucose and dyslipidemia but not with other adipokines. Moreover, irisin decreased during an OGTT in a subcohort comprising subjects with normal glucose tolerance, impaired fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus. rs726344 was not associated with serum irisin levels or with other anthropometric and biochemical parameters. CONCLUSIONS: Circulating irisin levels are associated with a beneficial metabolic profile but not with other adipokines and not with rs726344 in our cohort. Our data suggest a potential favorable role of irisin in the regulation of metabolism.
BACKGROUND/ OBJECTIVES:Irisin has been suggested as a novel myokine with beneficial effects in rodents. However, previous data in humans showed conflicting results regarding its association with metabolic phenotypes and regulation of secretion. Furthermore, although an association of rs726344 in FNDC5 (fibronectin type III domain containing 5) coding for irisin with insulin sensitivity was reported, the effects of genetic variation at this locus on irisin serum levels have not been investigated, so far. Therefore, we investigated circulating irisin and the associations with rs726344 in a cohort of >1000 subjects. SUBJECTS/ METHODS:Irisin serum concentrations were measured with enzyme-linked immunosorbent assay. Associations with metabolic parameters including renal function, glucose and lipid metabolism, inflammation, as well as adipokine profiles, were assessed in regression models. Dynamic changes of serum irisin were investigated during oral glucose tolerance test (OGTT) in a subset of the cohort (n=136). rs726344 was genotyped in all subjects and analyzed for associations with serum irisin and traits of the metabolic syndrome. RESULTS:Irisin was negatively associated with fat mass, fasting glucose and dyslipidemia but not with other adipokines. Moreover, irisin decreased during an OGTT in a subcohort comprising subjects with normal glucose tolerance, impaired fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus. rs726344 was not associated with serum irisin levels or with other anthropometric and biochemical parameters. CONCLUSIONS: Circulating irisin levels are associated with a beneficial metabolic profile but not with other adipokines and not with rs726344 in our cohort. Our data suggest a potential favorable role of irisin in the regulation of metabolism.
Authors: Krishna R Veeramah; Anke Tönjes; Peter Kovacs; Arnd Gross; Daniel Wegmann; Patrick Geary; Daniela Gasperikova; Iwar Klimes; Markus Scholz; John Novembre; Michael Stumvoll Journal: Eur J Hum Genet Date: 2011-05-11 Impact factor: 4.246
Authors: Hae Yoon Choi; Sungeun Kim; Ji Woo Park; Nam Seok Lee; Soon Young Hwang; Joo Young Huh; Ho Cheol Hong; Hye Jin Yoo; Sei Hyun Baik; Byung-Soo Youn; Christos S Mantzoros; Kyung Mook Choi Journal: J Clin Endocrinol Metab Date: 2014-04-29 Impact factor: 5.958
Authors: Aimin Xu; Annette W K Tso; Bernard M Y Cheung; Yu Wang; Nelson M S Wat; Carol H Y Fong; Dennis C Y Yeung; Edward D Janus; Pak C Sham; Karen S L Lam Journal: Circulation Date: 2007-03-27 Impact factor: 29.690
Authors: Maximilian von Eynatten; Lutz P Breitling; Marcel Roos; Marcus Baumann; Dietrich Rothenbacher; Hermann Brenner Journal: Arterioscler Thromb Vasc Biol Date: 2012-06-07 Impact factor: 8.311
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Arturo Roca-Rivada; Cecilia Castelao; Lucía L Senin; María O Landrove; Javier Baltar; Ana Belén Crujeiras; Luisa María Seoane; Felipe F Casanueva; María Pardo Journal: PLoS One Date: 2013-04-11 Impact factor: 3.240
Authors: Anna Szumilewicz; Aneta Worska; Magdalena Piernicka; Agnieszka Kuchta; Jakub Kortas; Zbigniew Jastrzębski; Łukasz Radzimiński; Joanna Jaworska; Katarzyna Micielska; Ewa Ziemann Journal: Biomed Res Int Date: 2017-10-31 Impact factor: 3.411